⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDCX News
Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
globenewswire.com
MDCX
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
globenewswire.com
MDCX
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
accessnewswire.com
ACXP
DVLT
IGC
NRXP
SNYR
TRN
VTIX
VVOS
YYGH
MDCX
ATON
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
globenewswire.com
MDCX
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
MDCX
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
accessnewswire.com
MDCX
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
globenewswire.com
MDCX
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
accessnewswire.com
SAGT
MDCX
YYGH
NRXP
SNYR
SDST
DVLT
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
accessnewswire.com
MDCX
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
globenewswire.com
MDCX